Last reviewed · How we verify

Cytokine-induced killer cells+ FOLFOX4

China Meitan General Hospital · FDA-approved active Small molecule

Cytokine-induced killer cells+ FOLFOX4 is a Cell therapy combined with chemotherapy Small molecule drug developed by China Meitan General Hospital. It is currently FDA-approved for Colorectal cancer (in combination with FOLFOX4 chemotherapy). Also known as: CIK + Oxaliplatin + leucovorin + 5-FU.

Cytokine-induced killer cells combined with FOLFOX4 chemotherapy work synergistically to enhance anti-tumor immunity and direct cytotoxic killing of cancer cells.

Cytokine-induced killer cells combined with FOLFOX4 chemotherapy work synergistically to enhance anti-tumor immunity and direct cytotoxic killing of cancer cells. Used for Colorectal cancer (in combination with FOLFOX4 chemotherapy).

At a glance

Generic nameCytokine-induced killer cells+ FOLFOX4
Also known asCIK + Oxaliplatin + leucovorin + 5-FU
SponsorChina Meitan General Hospital
Drug classCell therapy combined with chemotherapy
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Cytokine-induced killer (CIK) cells are ex vivo expanded lymphocytes with natural killer and T-cell properties that recognize and kill tumor cells. When combined with FOLFOX4 (a chemotherapy regimen of 5-fluorouracil, leucovorin, and oxaliplatin), the chemotherapy reduces tumor burden while CIK cells provide immunological attack against remaining malignant cells, potentially reducing recurrence and improving overall survival.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cytokine-induced killer cells+ FOLFOX4

What is Cytokine-induced killer cells+ FOLFOX4?

Cytokine-induced killer cells+ FOLFOX4 is a Cell therapy combined with chemotherapy drug developed by China Meitan General Hospital, indicated for Colorectal cancer (in combination with FOLFOX4 chemotherapy).

How does Cytokine-induced killer cells+ FOLFOX4 work?

Cytokine-induced killer cells combined with FOLFOX4 chemotherapy work synergistically to enhance anti-tumor immunity and direct cytotoxic killing of cancer cells.

What is Cytokine-induced killer cells+ FOLFOX4 used for?

Cytokine-induced killer cells+ FOLFOX4 is indicated for Colorectal cancer (in combination with FOLFOX4 chemotherapy).

Who makes Cytokine-induced killer cells+ FOLFOX4?

Cytokine-induced killer cells+ FOLFOX4 is developed and marketed by China Meitan General Hospital (see full China Meitan General Hospital pipeline at /company/china-meitan-general-hospital).

Is Cytokine-induced killer cells+ FOLFOX4 also known as anything else?

Cytokine-induced killer cells+ FOLFOX4 is also known as CIK + Oxaliplatin + leucovorin + 5-FU.

What drug class is Cytokine-induced killer cells+ FOLFOX4 in?

Cytokine-induced killer cells+ FOLFOX4 belongs to the Cell therapy combined with chemotherapy class. See all Cell therapy combined with chemotherapy drugs at /class/cell-therapy-combined-with-chemotherapy.

What development phase is Cytokine-induced killer cells+ FOLFOX4 in?

Cytokine-induced killer cells+ FOLFOX4 is FDA-approved (marketed).

What are the side effects of Cytokine-induced killer cells+ FOLFOX4?

Common side effects of Cytokine-induced killer cells+ FOLFOX4 include Myelosuppression, Nausea and vomiting, Diarrhea, Peripheral neuropathy, Infusion-related reactions.

Related